How CEO Clay Siegall Seeks To Inform People About Scientific Advances

The Chief Executive Officer of Seattle Genetics, Clay Seigall, publishes an insightful blog that is filled with articles he has found about new developments in the world of science, technology, and medicine. As someone that is deeply experienced in the world of science, Clay Seigall is very much aware that climate change is real and is being primarily caused by human activity. A recent article he published was about James Brainard, the Republican of Carmel, Indiana who is working to prevent climate change. Like many mayors and governors across the United States, he is very much opposed to President Trump deciding to have the United State drop out of the Paris Accord which was agreed to by almost every nation on the planet.

Another article that Clay Seigall shared was one where astronomists discovered a planet that has a tail much like the ones comets do. The planet, which is one of the hottest ever found and even exceed the heat of most suns, is going so fast around its star that part of its atmosphere drags behind it in the form of a tail. Eventually, the star is likely to lose all of its gasses due to this.

Clay Siegall has made his professional career centered around finding targeted cures to diseases that people face. Older, conventional medicines can’t differentiate between diseased cells and healthy ones which far too often leads to poor outcomes for patients. Dr. Siegall’s medicines destroy only diseased cells which are not only safer for patients but far more effective. His company has one drug on the global market that treats lymphoma, called ADCETRIS. His team at Seattle Genetics is continuing to research this drug as it shows promise treating other types of cancer. Altogether, they have over 20 drugs under different phases of development at his company that are being researched to cure cancer and other deadly diseases.

As the top executive at Seattle Genetics, Clay Siegall is tasked with fundraising in order to fund their life-saving medical research. He has raised over $1.2 billion for his company. He has also developed strategic partnerships with other biotechnology companies in order to develop their drugs and make them widely available.